Immunic Therapeutics
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company has a pipeline that includes three small molecule products. Its lead program, IMU-838, is a selective immune modulator that works by inhibiting the enzyme DHODH, targeting conditions such as multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. The second product, IMU-935, functions as an inverse agonist of the transcription factor RORγt and is being developed for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Lastly, IMU-856 aims to restore intestinal barrier function and is intended for diseases associated with bowel barrier dysfunction. Through these innovative therapies, Immunic Therapeutics aims to address significant unmet medical needs in the field of immunology.
Vital Therapies, Inc. was a biotherapeutic company based in San Diego, California, focused on developing cell-based therapies for acute liver failure. The company's main product candidate, the ELAD System, is a bio-artificial liver therapy designed to operate outside the body and aimed at either allowing the patient's liver to regenerate or stabilizing the patient until a liver transplant can be performed. ELAD incorporates human liver-derived C3A cells and has shown potential to improve survival rates in patients with acute liver failure, having received orphan designation in both the United States and Europe. Prior to the initiation of its Phase III clinical trial program, over 150 subjects participated in clinical trials and compassionate use programs involving ELAD therapy. The company began three Phase III trials targeting various conditions related to acute liver failure, including alcohol-induced liver decompensation and acute alcoholic hepatitis. Vital Therapies was acquired by Immunic AG in 2019, which marked a significant transition in its corporate structure and focus.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.